Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Treatment of Patients With Newly Diagnosed Type 2 Diabetes: a Multicenter, Randomized Open Trial Study With Parallel Controls

The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.

Study Overview

• Status: Recruiting
• Conditions: Type 2 Diabetic Patients; T2DM (Type 2 Diabetes Mellitus); T2DM
• Intervention / Treatment: Drug: Beinaglutide; Drug: Insulin aspart

Detailed Description

Based on the dual roles of glucagon-like peptide 1 (GLP-1) in regulating fasting blood glucose and postprandial blood glucose secretion, we adopted a combinational therapeutic model and will administer drug treatments during meals. Newly diagnosed type 2 diabetic patients will be administered continuous subcutaneous Beinaglutide injections using a pump device. The efficacy, safety and disease control after terminating the drug treatments will be compared to those of patients who receive CSII treatment.

This is a national-level, multicenter, randomized, open study with parallel controls. The study consists of two phases:

a 8-week treatment phase and a 12-week post-treatment follow-up period.

• Study Type: Interventional
• Enrollment (Estimated): 115
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lixin Guo, M.D.，Ph.D.; Phone Number: +8613901317569; Email: glx1218@163.com
• Study Contact Backup: Name: Dongni Yu, M.D.; Phone Number: +8613621273587; Email: yudongni@outlook.com

Study Locations

• China
  • Beijing, China, 100034
    • Recruiting
    • First Hospital of Peking University
    • Contact: Geheng Yuan, Ph.D. M.D.; Phone Number: 13811235488; Email: 139197109@qq.com
  • Harbin, China, 150030
    • Recruiting
    • Heilongjiang Provincial Hospital
    • Contact: Binhong Duan, M.D, Ph.D.
  • Zhengzhou, China, 450003
    • Recruiting
    • Henan People's Hospital
    • Contact: Huijuan Yuan, Ph.D. M.D.
  • Beijing
    • Beijing, Beijing, China
      • Recruiting
      • Peking University Shougang Hospital
      • Contact: Xiuqin Sun, M.D.; Phone Number: +8613552300467; Email: sxqlyfxly@163.com
    • Beijing, Beijing, China, 000
      • Recruiting
      • Pinggu District Hospital
      • Contact: Yufeng Li, M.D.; Phone Number: +8613911080328; Email: doctorlyf@126.com
    • Beijing, Beijing, China
      • Recruiting
      • Capital Medical University Beijing Anzhen Hospital
      • Contact: Liping Ma, M.D.; Phone Number: +8613901249835; Email: maliping65@126.com
    • Beijing, Beijing, China
      • Recruiting
      • Emergency General Hospital
      • Contact: Kailiang Wang, M.D.; Phone Number: +8613911151692; Email: maliping65@126.com
  • Guangdong
    • Guangzhou, Guangdong, China, 000
      • Recruiting
      • Southern Medical University Nanfang Hospital
      • Contact: Yaoming Xue, M.D.; Phone Number: +8613926066999; Email: yaomingxue@126.com
  • Heilongjiang
    • Harbin, Heilongjiang, China
      • Recruiting
      • Harbin Medical University Second Hospital
      • Contact: Qiao Hong, M.D.; Phone Number: +8613359854888; Email: qiaoh0823@sina.com
  • Jiangsu
    • Nanjing, Jiangsu, China, 000
      • Recruiting
      • Southeast University Zhongda Hospital
      • Contact: Ling Li, M.D.; Phone Number: +8613951606816; Email: endocrine2023@163.com
    • Xuzhou, Jiangsu, China
      • Recruiting
      • Xuzhou Medical University Affiliated Hospital
      • Contact: Hongwei Ling, M.D.; Phone Number: +8618052268607; Email: ling_hongwei@126.com
  • Jilin
    • Changchun, Jilin, China
      • Recruiting
      • China-Japan Union Hospital of Jilin University
      • Contact: Qing Wang, M.D.; Phone Number: +8613614301117; Email: wang_qing@jlu.edu.cn
    • Changchun, Jilin, China
      • Recruiting
      • Jilin University Second Hospital
      • Contact: Hanqing Cai, M.D.; Phone Number: +8613674315050; Email: Caihanqing16@163.com
  • Shaanxi
    • Xian, Shaanxi, China, 000
      • Recruiting
      • Xi'an Jiaotong University Second Hospital
      • Contact: Jing Xu, M.D.; Phone Number: +8613772151682; Email: xujingjdey85@163.com
  • Sichuan
    • Luzhou, Sichuan, China, 000
      • Recruiting
      • Southwest Medical University Affiliated Hospital
      • Contact: Xu Yong, M.D.; Phone Number: +8613980255895; Email: xywyll@aliyun.com
  • Tianjin
    • Tianjin, Tianjin, China
      • Recruiting
      • Peking University BinHai Hospital
      • Contact: Su Wang, M.D.; Phone Number: +8615122328988; Email: wsrealm@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age 18 to 70 years (inclusive) at enrollment, regardless of gender.
2. Voluntary signing of the informed consent form.
3. Newly diagnosed type 2 diabetes mellitus patients, diagnosed according to the WHO 1999 criteria, with a disease duration ≤1 year.
4. HbA1c between 7.5% and 10.0%.
5. BMI between 24 kg/m² and 42 kg/m².
6. Subjects who have not taken antidiabetic medications or have used oral antidiabetic medications for less than 3 months and have discontinued for more than 1 month (calculated from the date of signing the informed consent form).
7. Subjects with reproductive potential (including male subjects whose partners have reproductive potential) agree to use effective contraception during the study and for 1 month after study completion.

Exclusion Criteria:

1. Patients with type 1 diabetes or other types of diabetes.
2. History of obstructive intestinal diseases or potential complications: subjects with post-abdominal surgery or peritoneal infection-related intestinal adhesions, intestinal obstruction sequelae; subjects with intestinal motility disorders, chronic constipation; subjects with a history of Crohn's disease or ulcerative colitis.
3. History of pancreatitis.
4. Family history of medullary thyroid carcinoma.
5. History of malignant tumors.
6. ALT, AST >3 times the upper limit of normal, and/or total bilirubin >2 times the upper limit of normal.
7. Moderate to severe renal insufficiency (eGFR <60 ml/min/1.73m²).
8. Triglycerides ≥5.0 mmol/L.
9. Multiple endocrine neoplasia type 2 (MEN 2).
10. Participation in any pre-marketing drug study within 3 months.
11. Use or expected use of systemic corticosteroids, immunosuppressants, or cytotoxic drugs during the study period.
12. History of diabetic ketoacidosis or non-ketotic hyperosmolar coma within 6 months prior to screening.
13. Blood pressure exceeding the following criteria (untreated or treated): systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg.
14. History of any of the following cardiovascular diseases within 3 months prior to screening: acute myocardial infarction, New York Heart Association functional class III/IV heart failure or left ventricular ejection fraction ≤40%, or cerebrovascular event (stroke).
15. Allergy to binaclotide or any component of the study drug, or allergy to insulin or any component of the insulin used in the study.
16. Presence of other severe diseases that may interfere with the study, as judged by the investigator.
17. Pregnant or breastfeeding women.
18. Poor compliance, as judged by the investigator, and inability to complete the study as required.
19. Inability to undergo continuous pump infusion: subjects allergic to subcutaneous infusion tubes or adhesive tape; subjects unwilling to have long-term subcutaneous infusion tubes or continuous pump use; subjects with psychological aversion to pump therapy; subjects or their families lack relevant knowledge and are unable to master the use after training; subjects with severe psychological disorders or mental abnormalities; subjects who are unable to care for themselves and have no caregivers.
20. Any other factors deemed unsuitable for participation in the study by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Continuouns Insulin aspart infusion; 8-week insulin aspart (CSII) treatment group	Drug: Insulin aspart; Insulin aspart (CSII)
Experimental: Continuous Beinaglutide infusion; 8-week Beinaglutide (continuous subcutaneous infusion) treatment group	Drug: Beinaglutide; Beinaglutide (continuous subcutaneous infusion)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The proportion of subjects achieving HbA1c <7.0%, no weight increase (≤0 kg), and no hypoglycemia (blood glucose ≤3.9 mmol/L or severe hypoglycemia) after 8 weeks of treatment.	The primary endpoint of the trial is a composite endpoint of HbA1c <7.0%, no weight increase (≤0 kg), and no hypoglycemia (blood glucose ≤3.9 mmol/L or severe hypoglycemia) after 8 weeks of treatment..	From baseline to the end of treatment at 8 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects achieving HbA1c reduction <7% after 8 weeks of treatment.	Proportion of participants achieving a reduction in HbA1c levels to below 7% after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in fasting blood glucose from baseline after 8 weeks of treatment.	Changes in fasting blood glucose from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in postprandial blood glucose from baseline after 8 weeks of treatment.	Changes in postprandial blood glucose from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in HbA1C from baseline after 8 weeks of treatment.	Changes in HbA1C from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Proportion of subjects with weight reduction ≥5% from baseline after 8 weeks of treatment.	Proportion of subjects with weight reduction ≥5% from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in weight from baseline after 8 weeks of treatment.	Changes in weight from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in waist circumference from baseline after 8 weeks of treatment.	Changes in waist circumference from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in waist-to-hip ratio from baseline after 8 weeks of treatment.	Changes in waist-to-hip ratio from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in fasting insulin from baseline after 8 weeks of treatment.	Changes in fasting insulin from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in fasting C-peptide from baseline after 8 weeks of treatment.	Changes in fasting C-peptide from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in HOMA-β from baseline after 8 weeks of treatment.	Changes in HOMA-β from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in HOMA-IR from baseline after 8 weeks of treatment.	Changes in HOMA-IR from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in lipid profile from baseline after 8 weeks of treatment.	Changes in lipid profile from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Changes in heart rate from baseline after 8 weeks of treatment.	Changes in heart rate from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week
Proportion of subjects achieving HbA1c <6.5% at 20 weeks.	Proportion of subjects achieving HbA1c <6.5% at 20 weeks.	From baseline to week 20
Proportion of subjects achieving HbA1c <7% at 20 weeks.	Proportion of subjects achieving HbA1c <7% at 20 weeks.	From baseline to week 20
Proportion of subjects with fasting blood glucose <7.0 mmol/L at 20 weeks.	Proportion of subjects with fasting blood glucose <7.0 mmol/L at 20 weeks.	From baseline to week 20
Changes in weight from baseline at 20 weeks.	Changes in weight from baseline at 20 weeks.	From baseline to week 20
Changes in BMI from baseline at 20 weeks.	Changes in BMI from baseline at 20 weeks.	From baseline to week 20
Changes in waist-to-hip ratio from baseline at 20 weeks.	Changes in waist-to-hip ratio from baseline at 20 weeks.	From baseline to week 20
Changes in fasting blood glucose from baseline at 20 weeks.	Changes in fasting blood glucose HbA1c from baseline at 20 weeks.	From baseline to week 20
Changes in postprandial blood glucose from baseline at 20 weeks.	Changes in postprandial blood glucose from baseline at 20 weeks.	From baseline to week 20
Changes in HbA1c from baseline at 20 weeks.	Changes in HbA1c from baseline at 20 weeks.	From baseline to week 20
Changes in HOMA-β from baseline at 20 weeks.	Changes in HOMA-β from baseline at 20 weeks.	From baseline to week 20
Changes in HOMA-IR from baseline at 20 weeks.	Changes in HOMA-IR from baseline at 20 weeks.	From baseline to week 20
Changes in fasting insulin from baseline at 20 weeks.	Changes in fasting insulin from baseline at 20 weeks.	From baseline to week 20
Changes in fasting C-peptide from baseline at 20 weeks.	Changes in fasting C-peptide from baseline at 20 weeks.	From baseline to week 20
Changes in lipid profile from baseline at 20 weeks.	Changes in lipid profile from baseline at 20 weeks.	From baseline to week 20
Changes in blood pressure baseline after 8 weeks of treatment.	Changes in blood pressure (assessing both of systolic and diastolic pressure) from baseline after 8 weeks of treatment.	From baseline to the end of treatment at 8 week

Collaborators and Investigators

• Sponsor: Beijing Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 2, 2019
• Primary Completion (Estimated): September 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: June 12, 2019
• First Submitted That Met QC Criteria: June 13, 2019
• First Posted (Actual): June 17, 2019

Study Record Updates

• Last Update Posted (Actual): May 2, 2025
• Last Update Submitted That Met QC Criteria: April 30, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: CSII; T2DM; beinaglutide; subcutaneous pump
• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Diabetes Mellitus, Type 2; Physiological Effects of Drugs; Hypoglycemic Agents; Insulin Aspart
• Other Study ID Numbers: BN-IIT-IS-008

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No